Money Stuff: The Podcast · Friday, July 31, 2026
Exoma, a biotech royalty company, has been involved in a confusing situation regarding the record date for its contingent value rights (CVRs) related to its acquisition by Ligand. This has led to a discrepancy in what shareholders receive depending on when they bought the stock, causing trading confusion and requiring clarification.
“So there's two biotech royalty companies like Sooma has this like litigation going on. So what they did is they sold themselves to Ligan for thirty nine dollars a share in cash plus like a claim on that litigation. It's called the CVR continued.”
“The record date for the distribution of the contingent value rights is five PM on July thirteenth, which is the day before the merger closing date.”
“And then like two days after the merger closed, they put out a shameful press release saying, nope, never mind, we're not using the record date. This was all wrong, like mergers close when they close.”